title: To conduct clinical trial in China, to go or not to go.
abstract: In the last 10 years, more and more clinical trials have come to China because of potential market/easy access of patient and cost-effectiveness, but if we look back, there had been minimum changes on the regulatory requirements, and there is a possibility that China government could further strengthen the regulatory requirements for the global pharma/foreign pharma. In 2013, there was a breaking news that China government would start to investigate the corruption of GSK. So now, should the global pharma/foreign pharma go to China to conduct clinical trial? If the sponsor wants to access China market and provide unmet medical needs to China market, there are still many opportunities and there are ways to get all of these barriers resolved.
authors.affiliation: Room 102, No. 27, Lane 199, Baiyang Road, Shanghai, China 201204. Liangkongliang@hotmail.com.
authors.forename: Liang
authors.initials: L
authors.lastname: Kong
mesh_terms: D002681:China; D002986:Clinical Trials as Topic / Q000331:legislation & jurisprudence / Q000592:standards; D004345:Drug Industry; D006801:Humans; D018579:Patient Selection